Carcinoma in situ of the urinary bladder: Review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 7, Issue 1, 2009, Pages 48-54

  Nese, Nalan ^a,b   Gupta, Ruta ^a   Bui, Matthew H T ^a   Amin, Mahul B ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b CELAL BAYAR UNIVERSITY   (Turkey)

Author keywords

Carcinoma in situ; Molecular mechanisms; Prognostic factors; Urinary bladder

Indexed keywords

ALPHA INTERFERON; AMINOLEVULINIC ACID HEXYL ESTER; BCG VACCINE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOPHOSPHAMIDE; DOXORUBICIN; MITOMYCIN C; NUCLEAR MATRIX PROTEIN 22; PROTEIN P21; PROTEIN P53; TELOMERASE; UVOMORULIN;

BLADDER BIOPSY; BLADDER CARCINOMA; CANCER CELL; CANCER CHEMOTHERAPY; CARCINOMA IN SITU; CELL PROLIFERATION; CLINICAL FEATURE; CYSTECTOMY; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DISEASE FREE SURVIVAL; DYSURIA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION; HEMATURIA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LONG TERM EXPOSURE; NOCTURIA; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PROGNOSIS; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SMOKING; URINALYSIS; URINARY FREQUENCY; URINARY URGENCY; URINE CYTOLOGY; UROTHELIUM;

EID: 58149350053     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2009.0004     Document Type: Review

References (63)

1. Sesterhenn. IA. Urothelial carcinoma in situ. In: Eble J, Sauter G, Epstein J, Sesterhenn I, eds. World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Urinary System and the Male Genital Organs. Lyons: IARC; 2004:119-120.
2. Amin MB, Young RH. Intraepithelial lesions of the urinary bladder with a discussion of the histogenesis of urothelial neoplasia. Semin Diagn Pathol 1997;14:84-97.
3. Reuter V. The urothelial tract: renal pelvis, ureter, urinary bladder, and urethra. In: Mills S, Carter D, Reuter V, et al., eds. Sternberg's Diagnostic Surgical Pathology, Vol. 3 Philadelphia: Lippincott Williams & Wilkins; 2004:2036-2081.
4. Koch MO, Smith JA Jr. Natural history and surgical management of superficial bladder cancer (stages Ta/T1/CIS). In: Vogelzang NJ, Debruyne FM, Shipley WU, Scardino P, eds. Comprehensive Textbook of Genitourinary Oncology. Baltimore: Lippincott Williams and Wilkins; 1996:405-415.
5. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000;164(3 Pt 1):680-684.
6. Sylvester RJ, van der Meijden A, Witjes JA, et al. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 2005;66(6 Suppl 1):90-107.
7. Melicow M. Histological study of vesical urothelium intervening between gross neoplasms in total cystectomy. J Urol 1952;68:261-279.
8. Melicow M, Hollowell J. Intraurothelial cancer: carcinoma in situ, Bowen's disease of the urinary system: discussion of thirty cases. J Urol 1952;68:763-773.
9. Koss LG. Bladder cancer from a perspective of 40 years. J Cell Biochem Suppl 1992;161:23-29.
10. Koss LG, Tiamson EM, Robbins MA. Mapping cancerous and pre-cancerous bladder changes. A study of the urothelium in ten surgically removed bladders. JAMA 1974;227:281-286.
11. Murphy WM, Nagy GK, Rao MK, et al. "Normal" urothelium in patients with bladder cancer: a preliminary report from the National Bladder Cancer Collaborative Group A. Cancer 1979;44:1050-1058.
12. Jung I, Messing E. Molecular mechanisms and pathways in bladder cancer development and progression. Cancer Control 2003;7:325-334.
13. Brandau S, Bohle A. Bladder cancer. I. Molecular and genetic basis of carcinogenesis. Eur Urol 2001;39:491-497.
14. Hartmann A, Schlake G, Zaak D, et al. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in Situ of human urinary bladder. Cancer Res 2002;62:809-818.
15. Chang YH, Wu CH, Lee YL, et al. Evaluation of nuclear matrix protein-22 as a clinical diagnostic marker for bladder cancer. Urology 2004;64:687-692.
16. Landman J, Chang Y, Kavaler E, et al. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology 1998;52:398-402.
17. Lamm DL. Carcinoma in situ. Urol Clin North Am 1992;19:499-508.
18. Orozco RE, Martin AA, Murphy WM. Carcinoma in situ of the urinary bladder. Clues to host involvement in human carcinogenesis. Cancer 1994;74:115-122.
19. Murphy WM, Beckwith J, Farrow G. Tumots of the kidney, bladder and related urinary structures (Third Series). Washington, DC: Armed Forces Institute of Pathology; 1994.
20. Reznikoff CA, Sarkar S, Julicher KP, et al. Genetic alterations and biological pathways in human bladder cancer pathogenesis. Urol Oncol 2000;5:191-203.
21. Neoplasia. In: Kumar V, Abbas A, Fausto N, eds. Robbins and Cotran Pathologic Basis of Disease, 7th ed. Philadelphia: Elsevier Inc.; 2004:269-343.
22. Sarkar S, Julicher KP, Burger MS, et al. Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers. Cancer Res 2000;60:3862-3871.
23. Zaak D, Hungerhuber E, Schneede P, et al. Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions. Cancer 2002;95:1234-1238.
24. Jocham D, Witjes F, Wagner S, et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 2005;174:862-866; discussion 866.
25. Lopez-Beltran A, Bassi PF, Pavone-Macaluso M, Montironi R. Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. A joint proposal of the European Society of Uropathology and the Uropathology Working Group. Virchows Arch 2004;445:103-110.
26. Garbar C, Mascaux C, Wespes E. Is urinary tract cytology still useful for diagnosis of bladder carcinomas? A large series of 592 bladder washings using a five-category classification of different cytological diagnoses. Cytopathology 2007;18:79-83.
27. Cheng L, Cheville JC, Neumann RM, Bostwick DG. Flat intraepithelial lesions of the urinary bladder. Cancer 2000;88:625-631.
28. Epstein JI, Amin MB, Reuter VE, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 1998;22:1435-1448.
29. Levi AW, Potter SR, Schoenberg MP, Epstein JI. Clinical significance of denuded urothelium in bladder biopsy. J Urol 2001;166:457-460.
30. McKenney JK, Gomez JA, Desai S, et al. Morphologic expressions of urothelial carcinoma in situ: a detailed evaluation of its histologic pattern with emphasis on carcinoma in Situ with microinvasion. Am J Surg Pathol 2001;25:356-362.
31. Amin MB, McKenney JK. An approach to the diagnosis of flat intraepithelial lesions of the urinary bladder using the World Health Organization/International Society of Urological Pathology consensus classification system. Adv Anat Pathol 2002;9:222-232.
32. Guo CC, Fine SW, Epstein JI. Noninvasive squamous lesions in the urinary bladder: a clinicopathologic analysis of 29 cases. Am J Surg Pathol 2006;30:883-891.
33. Zincke H, Utz DC, Farrow GM. Review of Mayo Clinic experience with carcinoma in situ. Urology 1985;26(4 Suppl):39-46.
34. Amin MB, Gomez JA, Young RH. Urothelial transitional cell carcinoma with endophytic growth patterns: a discussion of patterns of invasion and problems associated with assessment of invasion in 18 cases. Am J Surg Pathol 1997;21:1057-1068.
35. McKenney JK, Desai S, Cohen C, Amin MB. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, PS3, and CD44 antigens. Am J Surg Pathol 2001;25:1074-1078.
36. Harnden P, Eardley I, Joyce AD, Southgate J. Cytokeratin 20 as an objective marker of urothelial dysplasia. Br J Urol 1996;78:870-875.
37. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol 1994;152(2 Pt 1):388-392.
38. Yin H, He Q, Li T, Leong AS. Cytokeratin 20 and Ki-67 to distinguish carcinoma in situ from flat non-neoplastic urothelium. Appl Immunohistochem Mol Morphol 2006;14:260-265.
39. Mallofre C, Castillo M, Morente V, Sole M. Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia. Mod Pathol 2003;16:187-191.
40. Sun W, Herrera GA. E-cadherin expression in urothelial carcinoma in situ, superficial papillary transitional cell carcinoma, and invasive transitional cell carcinoma. Hum Pathol 2002;33:996-1000.
41. Shariat SF, Pahlavan S, Baseman AG, et al. E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology 2001;57:60-65.
42. Alvarez A, Lokeshwar VB. Bladder cancer biomarkers: current developments and future implementation. Curr Opin Urol 2007;17:341-346.
43. Yoder BJ, Skacel M, Hedgepeth R, et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 2007;127:295-301.
44. Lokeshwar VB, Habuchi T, Grossman HB, et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 2005;66(6 Suppl 1):35-63.
45. Black PC, Brown GA, Dinney CP. Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. J Clin Oncol 2006;24:5528-5535.
46. Jakse G, Hall R, Bono A, et al. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861. Eur Urol 2001;40:144-150.
47. Smith JA Jr, Labasky RF, Cockett AT, et al. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol 1999;162:1697-1701.
48. van der Meijden AP, Sylvester R, Oosterlinck W, et al. EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ. Eur Urol 2005;48:363-371.
49. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol 2000;163:1124-1129.
50. American Urological Association. Clinical Guidelines: Bladder Cancer (2007). Available at: http://www.auanet.org/content/ guidelines-and-quality-care/clinical-guidelines.cfm. Accessed October 31, 2008.
51. Herr HW, Badalament RA, Amato DA, et al. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J Urol 1989;141:22-29.
52. Oosterlinck W, Lobel B, Jackse G, et al. [EAU Recommendations 2001. "Guidelines on bladder cancer"]. Ping Urol 2002;12:1161-1163 [in French].
53. Joudi FN, Konety BR. The impact of provider volume on outcomes from urological cancer therapy. J Urol 2005;174:432-438.
54. Chang SS, Cookson MS. Radical cystectomy for bladder cancer: the case for early intervention. Urol Clin North Am 2005;32:147-155.
55. Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 2001;166:1296-1299.
56. Nieder AM, Simon MA, Kim SS, et al. Radical cystectomy after bacillus Calmette-Guerin for high-risk Ta, T1, and carcinoma in Situ: defining the risk of initial bladder preservation. Urology 2006;67:737-741.
57. O'Donnell MA, Krohn J, DeWolf WC. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol 2001;166: 1300-1304, discussion 1304-1305.
58. Berger AP, Steiner H, Stenzl A, et al. Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study. Urology 2003;61:338-341.
59. Weinstein RS, Miller AW III, Pauli BU. Carcinoma in situ: comments on the pathobiology of a paradox. Urol Clin North Am 1980; 7:523-531.
60. Cheng L, Cheville JC, Neumann RM, et al. Survival of patients with carcinoma in situ of the urinary bladder. Cancer 1999;85:2469-2474.
61. Davis JW, Sheth SI, Doviak MJ, Schellhammer PF. Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year followup. J Urol 2002;167(2 Pt 1):494-500; discussion 501.
62. Andius P, Damm O, Holmang S. Prognostic factors in patients with carcinoma in situ treated with intravesical bacille Calmette-Guerin. Scand J Urol Nephrol 2004;38:285-290.
63. Dyrskjot L, Kruhoffer M, Thykjaer T, et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 2004;64:4040-4048.